Hematopoietic cell transplant therapy specialist Jasper Therapeutics (Nasdaq:JSPR) has made several changes to its management team.
The Redwood City, California–based company has promoted Jeet Mahal to chief operating officer. Mahal previously served as the company’s chief financial and business officer.
Jasper has also elevated Dr. Wendy Pang to be the company’s senior vice president of research and translational medicine. Pang formerly had a similar role, minus the “senior” title.
In addition, Dr. Judith Shizuru, scientific advisory board chair, will lead the company’s clinical development for the time being.
Finally, Dr. Kevin Heller, executive vice president of research and development, will transition to a consultant role.
In late February, the company announced the appointment of Ronald Martell as CEO.
In a news release, Martell explained that the recent organizational structure changes would support continued progress in the development of JSP191, an anti-CD117 monoclonal antibody and its mRNA hematopoietic stem cell program.
The company is planning a pivotal trial for JSP191 as a potential treatment for adult acute myeloid leukemia and myelodysplastic syndromes, which refer to a group of bone marrow failure disorders.
Jasper went public via a reverse SPAC merger with Amplitude Healthcare Acquisition in 2021.
Since the beginning of the year, the stock has lost 56.3% of its value, falling to $3.50.
Filed Under: Cell & gene therapy
